Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (6198)	11/3/1998 6:37:00 PM
From: Anthony Wong	Respond to of 9523

Better Blood Sugar Control Helps Type II Diabetes Patients Fast Bloomberg News November 3, 1998, 5:17 p.m. ET Better Blood Sugar Control Helps Type II Diabetes Patients Fast Chicago, Nov. 3 (Bloomberg) -- Drug therapy to better control blood sugar levels immediately improves quality of life for patients with Type 2 diabetes and reduces the number of days missed from work, a study showed. Using Pfizer Inc.'s Glucotrol, researchers from the Harvard School of Public Health and their colleagues tested 594 patients with mild Type 2 diabetes. About half the patients were treated with diet management and Glucotrol, which helps the body produce insulin to process blood sugar. The others received diet management and a placebo. Type 2 diabetes, the most common form, mainly strikes overweight people during middle age and often is treated with diet and exercise. Patients either don't make enough insulin, or their bodies can't properly use the insulin they have. At the end of the 12-week study, researchers found those getting Glucotrol felt better, were less depressed, thought more clearly, needed fewer doctor visits and missed fewer days of work than those who got diet management alone. Researchers knew controlling blood sugar levels could reduce the long-term risk of debilitating complications of diabetes, such as kidney disease and blindness. The new study shows such control can have even faster and different benefits for patients with Type 2 diabetes. The study, sponsored by New York-based Pfizer, appears in tomorrow's Journal of the American Medical Association. --Michelle Fay Cortez in Ithaca, New York (607) 272-1174, through